STOCK TITAN

[SCHEDULE 13G] Lyell Immunopharma, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Lyell Immunopharma, Inc. Schedule 13G reports that Explore Investments LLC and Jeffrey P. Bezos each may be deemed to beneficially own 1,040,964 shares of Lyell common stock, representing 5.4% of the outstanding class as of the Event Date. Explore is the direct holder and Mr. Bezos is the sole member of Explore. Of the shares reported, 938,438 were acquired in the initial closing of a private placement on the Event Date. The filing notes the calculation basis of 14,808,006 total shares outstanding and disclaims beneficial ownership beyond the shares reported.

Lyell Immunopharma, Inc. Nel modulo Schedule 13G si segnala che Explore Investments LLC e Jeffrey P. Bezos possono essere considerati titolari benefici di 1.040.964 azioni ordinarie di Lyell, corrispondenti al 5,4% della classe in circolazione alla Data dell'Evento. Explore è il possessore diretto e il sig. Bezos è l'unico socio di Explore. Delle azioni dichiarate, 938.438 sono state acquisite nella chiusura iniziale di un collocamento privato in tale Data. La dichiarazione indica una base di calcolo di 14.808.006 azioni totali in circolazione e declina la titolarità beneficiaria oltre le azioni riportate.

Lyell Immunopharma, Inc. El informe Schedule 13G indica que Explore Investments LLC y Jeffrey P. Bezos pueden ser considerados propietarios beneficiarios de 1.040.964 acciones ordinarias de Lyell, que representan el 5,4% de la clase en circulación en la Fecha del Evento. Explore es el titular directo y el Sr. Bezos es el único miembro de Explore. De las acciones informadas, 938.438 se adquirieron en el cierre inicial de una colocación privada en la Fecha del Evento. La presentación señala una base de cálculo de 14.808.006 acciones totales en circulación y niega la propiedad beneficiaria más allá de las acciones notificadas.

Lyell Immunopharma, Inc. Schedule 13G 보고서는 Explore Investments LLC와 Jeffrey P. Bezos가 각각 Lyell 보통주 1,040,964주를 실질적으로 보유한 것으로 간주될 수 있으며, 이는 사건일 현재 발행주식의 5.4%에 해당한다고 보고합니다. Explore는 직접 보유자이며 Bezos 씨는 Explore의 유일한 구성원입니다. 보고된 주식 중 938,438주는 사건일에 실시된 사모 발행의 초기 클로징에서 취득된 것입니다. 제출서류는 총 발행주식 수 14,808,006주를 계산 기준으로 명시하고 보고된 주식을 초과하는 실질 소유권은 부인합니다.

Lyell Immunopharma, Inc. Le Schedule 13G indique qu'Explore Investments LLC et Jeffrey P. Bezos peuvent être considérés comme détenteurs bénéficiaires de 1 040 964 actions ordinaires de Lyell, représentant 5,4% de la catégorie en circulation à la date de l'événement. Explore est le détenteur direct et M. Bezos est l'unique membre d'Explore. Parmi les actions déclarées, 938 438 ont été acquises lors de la clôture initiale d'un placement privé à la date de l'événement. le dépôt précise une base de calcul de 14 808 006 actions totales en circulation et décline toute propriété bénéficiaire au-delà des actions déclarées.

Lyell Immunopharma, Inc. Im Schedule 13G wird angegeben, dass Explore Investments LLC und Jeffrey P. Bezos jeweils als wirtschaftliche Eigentümer von 1.040.964 Lyell-Stammaktien angesehen werden können, was zum Stichtag 5,4% der ausstehenden Klasse entspricht. Explore ist der direkte Inhaber und Herr Bezos ist das einzige Mitglied von Explore. Von den gemeldeten Aktien wurden 938.438 bei dem erstmaligen Abschluss einer Privatplatzierung am Ereignisdatum erworben. Die Einreichung nennt eine Berechnungsgrundlage von insgesamt 14.808.006 ausstehenden Aktien und lehnt wirtschaftliches Eigentum über die gemeldeten Aktien hinaus ab.

Positive
  • Disclosure of 1,040,964 shares (5.4%) provides clear transparency on a significant holder
  • Identifies source of holdings including 938,438 shares acquired in the PIPE initial closing
  • Filing follows Schedule 13G format and includes calculation basis of 14,808,006 shares outstanding
Negative
  • None.

Insights

TL;DR: A single investor vehicle and its sole member report a 5.4% stake after a PIPE purchase, a potentially material passive stake.

The filing documents a passive stake of 1,040,964 shares equal to 5.4% of Lyell's common stock, calculated on 14,808,006 shares outstanding after recent issuances. The position includes 938,438 shares acquired in the PIPE initial closing. The Schedule 13G certification indicates the shares were not acquired to influence control, consistent with passive reporting. This disclosure is important for shareholder ownership concentration and may affect liquidity and block trade dynamics but contains no operational or financial performance data.

TL;DR: Disclosure shows a disclosed passive investor exceeding 5% threshold, triggering required public reporting without claiming control.

The statement clarifies Explore Investments LLC as the direct holder and Jeffrey P. Bezos as the sole member, which explains joint reporting. The filing expressly disclaims any intent to influence control and follows Form 13G standards for passive investors. It references related PIPE documentation and rights but does not assert control or group arrangements. This transparency satisfies SEC ownership disclosure norms and informs other stakeholders of a significant passive holder.

Lyell Immunopharma, Inc. Nel modulo Schedule 13G si segnala che Explore Investments LLC e Jeffrey P. Bezos possono essere considerati titolari benefici di 1.040.964 azioni ordinarie di Lyell, corrispondenti al 5,4% della classe in circolazione alla Data dell'Evento. Explore è il possessore diretto e il sig. Bezos è l'unico socio di Explore. Delle azioni dichiarate, 938.438 sono state acquisite nella chiusura iniziale di un collocamento privato in tale Data. La dichiarazione indica una base di calcolo di 14.808.006 azioni totali in circolazione e declina la titolarità beneficiaria oltre le azioni riportate.

Lyell Immunopharma, Inc. El informe Schedule 13G indica que Explore Investments LLC y Jeffrey P. Bezos pueden ser considerados propietarios beneficiarios de 1.040.964 acciones ordinarias de Lyell, que representan el 5,4% de la clase en circulación en la Fecha del Evento. Explore es el titular directo y el Sr. Bezos es el único miembro de Explore. De las acciones informadas, 938.438 se adquirieron en el cierre inicial de una colocación privada en la Fecha del Evento. La presentación señala una base de cálculo de 14.808.006 acciones totales en circulación y niega la propiedad beneficiaria más allá de las acciones notificadas.

Lyell Immunopharma, Inc. Schedule 13G 보고서는 Explore Investments LLC와 Jeffrey P. Bezos가 각각 Lyell 보통주 1,040,964주를 실질적으로 보유한 것으로 간주될 수 있으며, 이는 사건일 현재 발행주식의 5.4%에 해당한다고 보고합니다. Explore는 직접 보유자이며 Bezos 씨는 Explore의 유일한 구성원입니다. 보고된 주식 중 938,438주는 사건일에 실시된 사모 발행의 초기 클로징에서 취득된 것입니다. 제출서류는 총 발행주식 수 14,808,006주를 계산 기준으로 명시하고 보고된 주식을 초과하는 실질 소유권은 부인합니다.

Lyell Immunopharma, Inc. Le Schedule 13G indique qu'Explore Investments LLC et Jeffrey P. Bezos peuvent être considérés comme détenteurs bénéficiaires de 1 040 964 actions ordinaires de Lyell, représentant 5,4% de la catégorie en circulation à la date de l'événement. Explore est le détenteur direct et M. Bezos est l'unique membre d'Explore. Parmi les actions déclarées, 938 438 ont été acquises lors de la clôture initiale d'un placement privé à la date de l'événement. le dépôt précise une base de calcul de 14 808 006 actions totales en circulation et décline toute propriété bénéficiaire au-delà des actions déclarées.

Lyell Immunopharma, Inc. Im Schedule 13G wird angegeben, dass Explore Investments LLC und Jeffrey P. Bezos jeweils als wirtschaftliche Eigentümer von 1.040.964 Lyell-Stammaktien angesehen werden können, was zum Stichtag 5,4% der ausstehenden Klasse entspricht. Explore ist der direkte Inhaber und Herr Bezos ist das einzige Mitglied von Explore. Von den gemeldeten Aktien wurden 938.438 bei dem erstmaligen Abschluss einer Privatplatzierung am Ereignisdatum erworben. Die Einreichung nennt eine Berechnungsgrundlage von insgesamt 14.808.006 ausstehenden Aktien und lehnt wirtschaftliches Eigentum über die gemeldeten Aktien hinaus ab.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934 (as amended, the "Exchange Act") and based on an aggregate total of 14,808,006 shares of the common stock of Lyell Pharmaceuticals, Inc. (the "Issuer") outstanding as of May 30, 2025, as reported by the Issuer in its preliminary prospectus (the "Prospectus") (File No. 333-288769) dated July 18, 2025, incorporated in the Issuer's Form S-3 registration statement filed with the Securities and Exchange Commission (the "SEC") on July 18, 2025, and after giving effect to the issuance of: (i) an additional 625,000 shares (the "ImmPACT Shares") of common stock on July 2, 2025 as reported in the Prospectus and (ii) an additional 3,753,752 shares (the "PIPE Shares") of common stock on July 25, 2025 upon completion of the Issuer's private placement transaction as reported by the Issuer in its Current Report filed with the SEC on Form 8-K (File No. 001-40502) on July 25, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: For purposes of Rule 13d-3 under the Exchange Act, all shares of the Issuer's common stock held by Explore may be deemed to be beneficially owned by Jeffrey P. Bezos as the sole member of Explore. The percentage reported in Row 11 is calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act, and based on an aggregate total of 14,808,006 shares of the common stock of the Issuer outstanding as of May 30, 2025, as reported in the Prospectus, and after giving effect to the issuance of: (i) the ImmPACT Shares on July 2, 2025 as reported in the Prospectus and (ii) the PIPE Shares on July 25, 2025, as reported by the Issuer in its Current Report filed with the SEC on Form 8-K (File No. 001-40502) on July 25, 2025.


SCHEDULE 13G



Explore Investments LLC
Signature:/s/ Paul Dauber
Name/Title:Paul Dauber/its Manager
Date:08/19/2025
Jeffrey P. Bezos
Signature:/s/ Jeffrey P. Bezos
Name/Title:Jeffrey P. Bezos/an Individual
Date:08/19/2025

FAQ

How many Lyell (LYEL) shares do Explore Investments LLC and Jeffrey P. Bezos report owning?

They each may be deemed to beneficially own 1,040,964 shares, representing 5.4% of the outstanding common stock as reported.

What portion of the reported stake was acquired in the PIPE transaction?

938,438 shares of the reported holdings were acquired in connection with the initial closing of the PIPE transaction on the Event Date.

What share count did the filing use to calculate the 5.4% ownership?

The percentage is based on an aggregate total of 14,808,006 shares outstanding as of May 30, 2025, as stated in the Prospectus and after specified issuances.

Does the Schedule 13G indicate the holders intend to influence control of Lyell?

No. The certification states the securities were not acquired to change or influence control and the filing is submitted under Schedule 13G standards for passive investors.

Who is the direct holder of the reported shares and what is Jeffrey P. Bezos's relation?

Explore Investments LLC is the direct holder and Jeffrey P. Bezos is identified as the sole member of Explore, so he may be deemed to beneficially own the shares.
Lyell Immunopharma, Inc.

NASDAQ:LYEL

LYEL Rankings

LYEL Latest News

LYEL Latest SEC Filings

LYEL Stock Data

203.25M
14.67M
14.87%
50.02%
0.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO